Maersk has sealed a deal with COVAXX to ship the American pharmaceutical firm’s Covid-19 vaccine around the world when and if it gets approval by regulatory authorities.
COVAXX is currently conducting Phase 1 clinical trials of its vaccine in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval. The company has advanced pre-commitments for over 100m doses round the globe. In September, COVAXX announced an agreement with Dasa, the largest diagnostic medical company in Brazil to conduct a large-scale human efficacy clinical trial in South America’s largest country.
Maersk will oversee all logistics activities to ensure efficient transportation to developing countries. The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
COVAXX is planning to manufacture 100m doses of its vaccine during early 2021, and a billion doses by the end of 2021.
“Efficient and safe delivery of Covid-19 vaccines around the world is the most urgent logistics challenge we face today. A. P. Moller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available,” said Rob Townley, head of special project logistics at Maersk.
This article originally appeared on Splash247